FIRS The Global Impact of Respiratory Disease – Second Edition

29. Standards of Practice for Case Management. Little Rock, Case Management Society of America, 2010. Available from: http://www.cmsa.org/portals/0/pdf/memberonly/StandardsOfPractice.pdf 30. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375: 1545–1555. Available from: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60206-1/abstract 31. Severe acute respiratory syndrome (SARS) webpage. Atlanta, Centers for Disease Control and Prevention. Available from: http://www.cdc.gov/sars/ 32. Antimicrobial resistance and antimicrobial consumption webpage. European Centre for Disease Prevention and Control. Available from: www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/Pages/index. aspx 33. Diel R, Nienhaus A, Lampenius N, Rusch-Gerdes S, Richter E. Cost of multi drug resistance tuberculosis in Germany. Respir Med 2014; 108: 1677–1687. Available from: http://www.resmedjournal.com/article/ S0954-6111(14)00333-3/abstract 34. Tanimura T, Jaramillo E, Weil D, Raviglione M, Lonnroth K. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J 2014; 43: 1763–1775. Available from: http://erj.ersjournals.com/content/43/6/1763.long 35. Guidelines on the management of latent tuberculosis infection. Geneva, World Health Organization, 2015. Available from: http://www.who.int/tb/publications/latent-tuberculosis-infection/en/ 36. TB CARE I. International Standards for Tuberculosis Care, Edition 3. TB CARE I, The Hague, 2014. Available from: http://www.who.int/tb/publications/ISTC_3rdEd.pdf 37. Moodley R, Godec TR, Team ST. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev 2016; 25: 29–35. Available from: http://err.ersjournals.com/content/25/139/29.long 38. The End TB Strategy. Geneva, World Health Organization, 2015. Available from: http://www.who.int/tb/ post2015_strategy/en/ 39. Implementing the end TB strategy: the essentials. Geneva, World Health Organization, 2015. Available from: http://who.int/tb/publications/2015/The_Essentials_to_End_TB/en/ 40. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classifi cation of malignant tumours. J Thorac Oncol 2007; 2: 706–714. Available from: http://www.sciencedirect.com/ science/article/pii/S1556086415312983 41. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung cancer mortality with low-dose comput ed tomographic screening. N Engl J Med 2011; 365: 395–409. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa1102873 42. Loomis D, Huang W, Chen G. The International Agency for Research on Cancer (IARC) evaluation of the carcinogenicity of outdoor air pollution: focus on China. Chin J Cancer 2014; 33: 189–196. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24694836 43. Global Alliance against Chronic Respiratory Diseases presentation. Available from: http://www.who.int/ gard/news_events/1-3.GARD-06-07-K1.pdf 44. Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med 2016; 4: 306–322. Available from: http://www.thelancet.com/journals/lanres/article/PIIS2213- 2600(15)00543-3/abstract 45. Mirsaeidi M, Motahari H, Taghizadeh Khamesi M, Sharifi A, Campos M, Schraufnagel DE. Climate change and respiratory infections. Ann Am Thorac Soc 2016; 13: 1223–1230. Available from: http://www. atsjournals.org/doi/abs/10.1513/AnnalsATS.201511-729PS 36 Forum of International Respiratory Societies

FIRS The Global Impact of Respiratory Disease – Second Edition | Page 37